Episcleral brachytherapy (EB) for retinoblastoma (RB)
Reviewed by Jonathan Chan

This retrospective study consisted of 11 eyes treated either with Iodine (I) -125 or Ruthenium (R) -106EB with a mean apical dose of 44Gy. There were five in group B (46%), three in group C (27%) and three in group D (27%). EB was primary in three eyes and eight were treated as secondary. Final visual acuity was better than 20/200 in 70% of cases, with globe preservation in nine cases. Local recurrence was reported in 18% of cases at a mean period of onset of 17.4 months. Two group D eyes recurred after secondary treatment and required enucleation. Radiation retinopathy occurred at a mean time of 17.4 months. Radiation-related complications included non-proliferative retinopathy in two eyes, proliferative retinopathy in three eyes and cataract in one eye. Recurrence free and ocular survival were found in 80% with overall survival of 100% over a five-year period after EB. The authors recommended a close follow-up period especially in the first six months post EB for recurrences and complications.

Episcleral brachytherapy for retinoblastoma.
Echegaray JJ, Al-Zahrani YA, Singh A.
BRITISH JOURNAL OF OPHTHALMOLOGY
2020;104:208-13.